Oral Transmucosal Drugs Market Report 2026

Oral Transmucosal Drugs Market Overview

• Oral Transmucosal Drugs market size has reached to $43.21 billion in 2025 • Expected to grow to $63.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: The Rising Incidence of Parkinson’s Disease Fueling Market Growth Due to Increasing Need for Rapid and Reliable Drug Delivery • Market Trend: Innovative Buccal And Sublingual Therapies Enhance Rapid Drug Absorption And Ease Of Use For Pediatric Seizure Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Transmucosal Drugs Market?

Oral transmucosal drugs refer to medications formulated to be absorbed through the mucous membranes in the mouth, providing swift effects and bypassing initial metabolism in the liver and gastrointestinal tract. These drugs are commonly used for conditions requiring rapid relief, such as pain management, and for patients who have difficulty swallowing pills. The main product types of oral transmucosal drugs are tablets, films, liquid and spray, and others. Tablets in the oral transmucosal drug refer to solid dosage forms intended for administration through the mucous membranes in the mouth. The indications are opioid dependence, nausea and vomiting, erectile dysfunction, neurological disorders, and others that are consumed via sublingual mucosa, buccal mucosa, and other routes of administration and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Oral Transmucosal Drugs Market Growth Forecast?

The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $63.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising focus on fast-acting drug delivery, increasing neurological and chronic pain cases, growing demand for patient-centric dosage forms, innovation in mucoadhesive technologies, expansion of home-based and emergency care therapies. Major trends in the forecast period include growing adoption of rapid-acting drug delivery systems, increasing use of sublingual and buccal films, rising demand for non-invasive alternatives to injections, expansion of transmucosal therapies for pain and neurological disorders, improved patient compliance through easy-to-administer formats.

What Is The Driver Of The Oral Transmucosal Drugs Market?

The rising incidence of Parkinson’s disease is expected to propel the growth of the oral transmucosal drug market going forward. Parkinson’s disease is a progressive neurological disorder characterized by tremors, rigidity, and slowed movement caused by the degeneration of dopamine-producing neurons in the brain. The rise in Parkinson’s cases is driven by aging populations, environmental exposures, genetic susceptibility, and improved diagnostic capabilities that enhance early detection. Oral transmucosal drug delivery helps support Parkinson’s disease management by enabling rapid absorption through the oral mucosa, bypassing gastrointestinal delays, and providing faster relief during “off” episodes when traditional oral tablets may be less effective. For instance, in January 2023, according to the American Parkinson Disease Association (APDA), a U.S.-based non-profit organization, a new epidemiological analysis identified nearly 90,000 new Parkinson’s diagnoses annually in the United States, reflecting a 50% increase compared to 2022. Therefore, the rising incidence of Parkinson’s disease is driving the growth of the oral transmucosal drug industry.

Key Players In The Global Oral Transmucosal Drugs Market

Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.

Global Oral Transmucosal Drugs Market Trends and Insights

Major companies in the oral transmucosal drug market are focusing on developing innovative solutions such as sublingual tablets to enhance rapid drug absorption and improve treatment adherence. Sublingual tablets are medications designed to dissolve under the tongue, allowing the drug to be absorbed directly into the bloodstream for a faster effect. For instance, in June 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Libervant (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters) in epilepsy patients aged 2 to 5 years. It is a thin, fast-dissolving film placed inside the cheek, where it securely adheres and delivers a consistent dose of diazepam quickly and reliably. This convenient, noninvasive treatment option offers superior usability and rapid absorption, providing an effective and discreet way to manage acute repetitive seizures in young pediatric patients.

What Are Latest Mergers And Acquisitions In The Oral Transmucosal Drugs Market?

In January 2024, XOMA Corporation, a US-based biotechnology company, acquired DSUVIA from Talphera, Inc. for $8 million. Through this acquisition, XOMA seeks to maximize revenue from DSUVIA, a sufentanil sublingual tablet, while sharing profits and risks with Talphera and leveraging potential milestones from Alora Pharmaceuticals. Talphera Inc. is a US-based pharmaceutical company involved in developing oral transmucosal drugs.

What Defines the Oral Transmucosal Drugs Market?

The oral transmucosal drugs market consists of sales of buccal patches, sublingual tablets, lozenges, and oral transmucosal powders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Transmucosal Drugs Market Report 2026?

The oral transmucosal drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral transmucosal drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.